NERV
Minerva Neurosciences, Inc. · Healthcare
No insider bought or sold Minerva Neurosciences, Inc. in the last 12 months
NERV over the last year
NERV after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
30 insider filings since 2016, newest first
Remy Luthringer · CEO
Geoff Race · President
David Kupfer · Director
Frederick W Ahlholm · SVP and Chief Accounting Officer
Geoff Race · EVP, CFO, CBO
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
Geoff Race · EVP, CFO, CBO
William F Doyle · Director
Joseph H. Reilly · SVP and COO
Index Venture Associates III Ltd · 10% owner
Index Venture Associates III Ltd · 10% owner
William F Doyle · Director
Joseph H. Reilly · SVP and COO
Geoff Race · EVP, CFO, CBO
Frederick W Ahlholm · SVP and Chief Accounting Officer
Mark S. Levine · SVP,GC, Sec.
Marc D Beer · Director
Geoff Race · EVP, CFO, CBO
Remy Luthringer · President and CEO
Mark S. Levine · SVP,GC, Sec.
Frederick W Ahlholm · SVP and Chief Accounting Officer
Rubertis Francesco De · Director and 10% owner
Michele Ollier · Director and 10% owner
Index Venture Associates III Ltd · 10% owner
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.